Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus TIPS in advanced hepatocellular carcinoma
NCT05882370Phase 2Recruiting
- Start
- Dec 2022
- Primary completion
- Jun 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in hepatocellular carcinoma (HCC). Primary endpoint: Objective Response Rate up to 2 years. Started Dec 2022; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05882370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05882370.